<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115136</url>
  </required_header>
  <id_info>
    <org_study_id>1576028</org_study_id>
    <nct_id>NCT05115136</nct_id>
  </id_info>
  <brief_title>Using Doxepin for Urticaria</brief_title>
  <official_title>The Use of Doxepin for Urticaria in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Isolated urticaria in the emergency department is widely treated by physicians with histamine&#xD;
      blocking agents such as diphenhydramine, cetirizine, and cimetidine. Doxepin is a tricyclic&#xD;
      antidepressant that has been shown to have much higher concentrations of histamine blocking&#xD;
      activity and therefore may be useful in treating urticaria. The purpose of this study is to&#xD;
      compare the effectiveness of using doxepin verses a traditional medication, diphenhydramine&#xD;
      (Benadryl), in the treatment of isolated urticaria in the emergency department.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 8, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of urticaria</measure>
    <time_frame>1 hour after med administration, 2 hours after administration, and prior to discharge.</time_frame>
    <description>Improvement of urticaria based on pruritis score. Scale is from 1-5, lower the score the better.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of urticaria</measure>
    <time_frame>1 hour after med administration, 2 hours after administration, and prior to discharge</time_frame>
    <description>Improvement of urticaria based percent of body area affected. Scale being utilized is the % of body area chart.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Urticaria</condition>
  <arm_group>
    <arm_group_label>Doxepin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg PO one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg PO one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxepin</intervention_name>
    <description>25mg dose of Doxepin will be administered one time, by mouth</description>
    <arm_group_label>Doxepin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>50 mg dose of Diphenhydramine will be administered one time, by mouth</description>
    <arm_group_label>Diphenhydramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18-65 years of age&#xD;
&#xD;
          -  Presenting to Upstate Adult Emergency Department at either the Downtown or Community&#xD;
             campuses.&#xD;
&#xD;
          -  Diagnosed with isolated/acute urticaria&#xD;
&#xD;
          -  Requires treatment with antihistamines to alleviate symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Patients with altered mental status/have impaired decision-making capacity.&#xD;
&#xD;
          -  Presenting with symptoms suggesting life threatening illness or anaphylaxis.&#xD;
&#xD;
          -  Patients who have received any antihistamine (H1 antagonist) within the past 2 hours&#xD;
             via any route of administration.&#xD;
&#xD;
          -  Patients who have received an H2 antagonist within the past 2 hours.&#xD;
&#xD;
          -  Patient received steroids by any route within the past 4 hours.&#xD;
&#xD;
          -  Patient received epinephrine within the past 20 minutes.&#xD;
&#xD;
          -  Patients currently taking concomitant p-glycoprotein inhibitors.&#xD;
&#xD;
          -  Patients on any of the following CYP2D6 inhibitors: Bupropion, Fluoxetine, Paroxetine,&#xD;
             Quinidine, Tipranavir.&#xD;
&#xD;
          -  Patients with a history of serotonin syndrome.&#xD;
&#xD;
          -  Patients currently taking another tricyclic antidepressant, selective serotonin&#xD;
             reuptake inhibitor, and/or serotonin-norepinephrine reuptake inhibitor.&#xD;
&#xD;
          -  Patients who have a condition where an antihistamine may be contraindicated.&#xD;
&#xD;
          -  Patients with a contraindication to anticholinergic medications.&#xD;
&#xD;
          -  History of adverse effects to tricyclic antidepressants or antihistamines.&#xD;
&#xD;
          -  Patient who, based on their medical history or in the opinion of the clinician, have&#xD;
             chronic urticaria, urticaria refractory to antihistamines, or dermatological disease&#xD;
             that interferes with evaluation of a therapeutic response.&#xD;
&#xD;
          -  Patients taking antileukotriene compounds (montelukast), calcineurin inhibitors&#xD;
             (tacrolimus) or anti-serotonin agents (cyproheptadine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Andonian, MD</last_name>
    <phone>315-464-4363</phone>
    <email>andoniad@upstate.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Pacelli, BA</last_name>
      <phone>315-464-6201</phone>
      <email>pacellil@upstate.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 5, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York - Upstate Medical University</investigator_affiliation>
    <investigator_full_name>David Andonian</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Doxepin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

